AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10739167 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 poor metabolizer genotype
Number of subjects: 976
Study 10739167 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 activity
Number of subjects: 976
Study 8638750 — intervention group
Group type: COMPARATOR
Intervention: Placebo arthroscopy
Number of subjects: 10
Study 8638750 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 10
Study 8638750 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard arthroscopic debridement
Number of subjects: 10
Study 1450091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10-40 mg/day, b.i.d.)
Number of subjects: 37
Study 1450091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-240 mg/day, b.i.d.)
Number of subjects: 37
Study 6420817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (various doses)
Number of subjects: 5
Study 6420817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6420817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (one dose level)
Number of subjects: 5
Study 30601431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of music
Number of subjects: 50
Study 30601431 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 50
Study 29575770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (albumin-free presentation)
Number of subjects: 30
Study 29575770 — intervention group
Group type: COMPARATOR
Intervention: Moroctocog alfa (previous technique)
Number of subjects: 30
Study 29575770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 26896742 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (single dose)
Number of subjects: 36
Study 26896742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 36
Study 24892763 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 24000
Study 24892763 — intervention group
Group type: COMPARATOR
Intervention: Control (hepatitis vaccine)
Number of subjects: 24000
Study 22846389 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered cognitive behavior therapy (CBT)
Number of subjects: 171
Study 22846389 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive behavior therapy (CBT)
Number of subjects: 171
Study 22846389 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 171
Study 20303080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered care
Number of subjects: 701
Study 20303080 — intervention group
Group type: COMPARATOR
Intervention: Standard care by general practitioners
Number of subjects: 701
Study 18549331 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG-531 (Romiplostim)
Number of subjects: 0
Study 15772927 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hemoglobin level (135-160 g/L) achieved with epoetin alfa (n=10)
Number of subjects: 33
Study 15772927 — intervention group
Group type: COMPARATOR
Intervention: Subnormal hemoglobin level (90-120 g/L) (n=14)
Number of subjects: 33
Study 11888871 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irinotecan/FUDR
Number of subjects: 185
Study 11888871 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 185
Study 10403869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-limited cuff
Number of subjects: 15
Study 10403869 — intervention group
Group type: COMPARATOR
Intervention: High-volume low-pressure cuff
Number of subjects: 15
Study 8775035 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine anaesthesia
Number of subjects: 62
Study 8775035 — intervention group
Group type: COMPARATOR
Intervention: Caudal anaesthesia
Number of subjects: 62
Study 2210620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 0
Study 6992978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan + CCNU + methotrexate
Number of subjects: 210
Study 6992978 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin and procarbazine
Number of subjects: 210
Study 6992978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 210
Study 31685304 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory pressure of 10 cm H2O
Number of subjects: 40
Study 31685304 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 15 cm H2O
Number of subjects: 40
Study 31824233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 23
Study 31824233 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Arm Training (BAT)
Number of subjects: 23
Study 28934782 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose ketoprofen (0.5 mg/kg every 6 hours for 48 hours)
Number of subjects: 100
Study 28934782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketoprofen (half doses and quarter doses)
Number of subjects: 100
Study 28934782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26424510 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and K-wire pinning
Number of subjects: 742
Study 26424510 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with a cast
Number of subjects: 742
Study 22873657 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + NBM
Number of subjects: 22
Study 22873657 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + β‐TCP
Number of subjects: 22
Study 20528206 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 30
Study 19805918 — intervention group
Group type: EXPERIMENTAL
Intervention: Better lung (lower LIS) down position
Number of subjects: 16
Study 19805918 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 16
Study 19805918 — intervention group
Group type: COMPARATOR
Intervention: Better lung-up position
Number of subjects: 16
Study 19805918 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning-related arterial oxygenation
Number of subjects: 16
Study 17761231 — intervention group
Group type: EXPERIMENTAL
Intervention: Established intervention
Number of subjects: 810
Study 17761231 — intervention group
Group type: EXPERIMENTAL
Intervention: Established intervention plus DASH dietary pattern
Number of subjects: 810
Study 17761231 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 810
Study 15801959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosupernatant plasma (CSP)
Number of subjects: 236
Study 15801959 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 236
Study 15801959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosupernatant plasma (CSP) and Fresh frozen plasma (FFP)
Number of subjects: 236
Study 12165991 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 100
Study 12165991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP
Number of subjects: 100
Study 12165991 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass F
Number of subjects: 100
Study 12165991 — intervention group
Group type: EXPERIMENTAL
Intervention: Elan
Number of subjects: 100
Study 12165991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 100
Study 9863784 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg inhaled zanamivir, twice daily for 5 days
Number of subjects: 455
Study 9863784 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 5 days
Number of subjects: 455
Study 8847377 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week community-based large group parent training (Community/Group)
Number of subjects: 0
Study 8847377 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week clinic-based individual parent training (Clinic/Individual)
Number of subjects: 0
Study 8847377 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 2195153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.075% sanguinaria extract and 2% zinc chloride, followed by a mouthrinse containing 0.03% sanguinaria extract and 0.2% zinc chloride.
Number of subjects: 60
Study 2195153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 60
Study 581636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpasteurized yogurt
Number of subjects: 54
Study 581636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized yogurt
Number of subjects: 54
Study 581636 — intervention group
Group type: COMPARATOR
Intervention: 2% butterfat milk
Number of subjects: 54
Study 581636 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake
Number of subjects: 54
Study 31851321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 550
Study 31851321 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-HER3 dimerization
Number of subjects: 550
Study 31851321 — intervention group
Group type: EXPERIMENTAL
Intervention: HER dimer imaging and conventional mutation analyses
Number of subjects: 550
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: High free androgen index (FAI ≥5%)
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: High free androgen index (FAI ≥5%) among women with high BMI
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: High free androgen index (FAI ≥5%) among women with normal BMI
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovary morphology
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovary morphology among women with normal BMI
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovary morphology among women with high BMI
Number of subjects: 947
Study 31444050 — intervention group
Group type: EXPERIMENTAL
Intervention: LH, sex hormone‐binding globulin (SHBG), and anti‐Müllerian hormone (AMH)
Number of subjects: 947
Study 28713084 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy + Acupuncture + Vestibular rehabilitation
Number of subjects: 109
Study 28713084 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy + Acupuncture
Number of subjects: 109
Study 28713084 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 109
Study 25380275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 643
Study 25380275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 23604551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral strategy with sitagliptin 100 mg/day
Number of subjects: 653
Study 23604551 — intervention group
Group type: COMPARATOR
Intervention: Injectable strategy with liraglutide starting at 0.6 mg/day, up-titrated to 1.2 mg/day after 1 week
Number of subjects: 653
Study 21767371 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded endoluminal bypass
Number of subjects: 222
Study 21767371 — intervention group
Group type: COMPARATOR
Intervention: Surgical femoro-popliteal bypass
Number of subjects: 222
Study 19836774 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 36 months
Number of subjects: 1468
Study 19836774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1468
Study 17097943 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNIs)
Number of subjects: 64
Study 17097943 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 64
Study 15236812 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram treatment
Number of subjects: 191
Study 15236812 — intervention group
Group type: COMPARATOR
Intervention: Control (no disulfiram treatment)
Number of subjects: 191
Study 10925508 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate (Baking Soda and Peroxide)
Number of subjects: 64
Study 10925508 — intervention group
Group type: EXPERIMENTAL
Intervention: Macleans (Whitening)
Number of subjects: 64
Study 10925508 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate (Sensation Whitening)
Number of subjects: 64
Study 10925508 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 64
Study 9351879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 43
Study 9351879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9351879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (in both Groups 2 and 3)
Number of subjects: 43
Study 9351879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (in Group 3)
Number of subjects: 43
Study 1852394 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training for control of accommodation
Number of subjects: 30
Study 1852394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback training)
Number of subjects: 30
Study 6843193 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized volunteer‐based emergency first‐responder system
Number of subjects: 36
Study 6843193 — intervention group
Group type: COMPARATOR
Intervention: Household telephone survey conducted immediately before project initiation, 3 months and 13 months after implementation
Number of subjects: 36
Study 30925120 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp intervention (4 persuasive messages sent via Bulk System)
Number of subjects: 548
Study 30925120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WhatsApp messages)
Number of subjects: 548
Study 30976031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble of diverse thermostatically controlled loads with varying disorder probability distributions (DPDs)
Number of subjects: 0
Study 30976031 — intervention group
Group type: COMPARATOR
Intervention: Control of the aggregator commanding devices to lower the rate r
Number of subjects: 0
Study 28129779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (exercise, health education, socialization and group auditory rehabilitation (GAR)) attending YMCA twice a week for 10 weeks.
Number of subjects: 0
Study 28129779 — intervention group
Group type: COMPARATOR
Intervention: Control group (GAR only) attending 60-min GAR sessions once a week for 10 weeks.
Number of subjects: 0
Study 28129779 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional fitness measures (gait speed, 30-s Sit to Stand Test)
Number of subjects: 0
Study 28129779 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness, depression, social participation and social support measures
Number of subjects: 0
Study 28129779 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility measures (recruitment, randomization, retention, acceptability)
Number of subjects: 0
Study 26936426 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg
Number of subjects: 505
Study 26936426 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg
Number of subjects: 505
Study 25263744 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin(®) 0.033 mg/kg/day) for 2 years
Number of subjects: 19
Study 25263744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment in the first year, double dose in the second year)
Number of subjects: 19
Study 22375973 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 184
Study 22375973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 20921838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SNB distal to bifurcation (group D)
Number of subjects: 50
Study 20921838 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided SNB proximal to bifurcation (group P)
Number of subjects: 50
Study 18540252 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 therapy with appropriate doses, improvement of clinical findings, normalization of serum total T4 levels, and persistently high TSH concentrations.
Number of subjects: 500
Study 18540252 — intervention group
Group type: COMPARATOR
Intervention: Control group with adequate suppression of TSH (<6 mU/l) with therapy.
Number of subjects: 500
Study 15723890 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 38
Study 15723890 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 12204500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 17
Study 12204500 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17
Study 10101319 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical technique (slide hammer and femoral rasps)
Number of subjects: 36
Study 10101319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical high frequency vibration rasp
Number of subjects: 36
Study 10101319 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical technique
Number of subjects: 36
Study 10101319 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical technique with high frequency vibration rasp
Number of subjects: 36
Study 10101319 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional surgical technique with distal venting hole
Number of subjects: 36
Study 8992429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide acetate
Number of subjects: 1199
Study 8992429 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium-chloride (control)
Number of subjects: 1199
Study 2109498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 112
Study 2109498 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 112
Study 599107 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent feedback with monetary rewards for appropriate pressure changes
Number of subjects: 40
Study 599107 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent beat‐to‐beat feedback with rewards equal to the mean of the contingent group
Number of subjects: 40
Study 599107 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent feedback presented randomly with respect to heart beats with rewards equal to the mean of the contingent group
Number of subjects: 40
Study 599107 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions alone with a bonus paid at the conclusion of the experiment
Number of subjects: 40
Study 30318128 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax bath treatment
Number of subjects: 36
Study 30318128 — intervention group
Group type: COMPARATOR
Intervention: Standard care with daily home exercises
Number of subjects: 36
Study 28104206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid sirolimus-eluting stent (SES) with biodegradable polymer
Number of subjects: 330
Study 28104206 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES) with durable polymer
Number of subjects: 330
Study 25447331 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust induction
Number of subjects: 0
Study 25447331 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotion induction
Number of subjects: 0
Study 25447331 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotion induction
Number of subjects: 0
Study 25447331 — intervention group
Group type: COMPARATOR
Intervention: Neutral control induction
Number of subjects: 0
Study 23149178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous omeprazole
Number of subjects: 40
Study 23149178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous omeprazole
Number of subjects: 40
Study 23149178 — intervention group
Group type: COMPARATOR
Intervention: Both doses of omeprazole
Number of subjects: 40
Study 21718094 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy started at diagnosis
Number of subjects: 24
Study 21718094 — intervention group
Group type: COMPARATOR
Intervention: Standard multiple daily insulin injections (MDIs)
Number of subjects: 24
Study 21718094 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 24
Study 19786862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1‐0.7 microg x kg(‐1) x h(‐1))
Number of subjects: 306
Study 19786862 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10‐70 microg x kg(‐1) x h(‐1))
Number of subjects: 306
Study 19786862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 306
Study 23108477 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) school meals for 3 months
Number of subjects: 834
Study 23108477 — intervention group
Group type: COMPARATOR
Intervention: Usual packed lunch (control) for 3 months
Number of subjects: 834
Study 15818288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 10 mg/kg once daily for 10 days
Number of subjects: 354
Study 15818288 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 90 mg/6.4 mg in 2 divided doses for 10 days
Number of subjects: 354
Study 12861138 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol tablet placed in the inner one third of the vagina
Number of subjects: 10
Study 12861138 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol tablet placed in the outer one third of the vagina
Number of subjects: 10
Study 9824602 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily for five days
Number of subjects: 13
Study 9824602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for five days
Number of subjects: 13
Study 9824602 — intervention group
Group type: COMPARATOR
Intervention: Control period with no treatment
Number of subjects: 13
Study 8563504 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing in chronic bronchitis patients
Number of subjects: 160
Study 8563504 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing in asthma patients
Number of subjects: 160
Study 2496740 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg recombinant tissue plasminogen activator (rt-PA) over five hours
Number of subjects: 57
Study 2496740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 871356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 69
Study 871356 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum
Number of subjects: 69